K D Munoz-Flores-Thiagarajan1, T Easterling, C Davis, E F Bond. 1. Department of Biobehavioral Nursing and Health Systems, School of Nursing, University of Washington, Box 357266, Seattle, WA 98195, USA. binga@u.washington.edu
Abstract
BACKGROUND: Cyclosporine is known to be excreted in breast milk, but levels in infants are not known. Post-transplant breast-feeding has been contraindicated in mothers treated with calcineurin inhibitors such as cyclosporine. CASE: A 35-year-old woman exclusively breast-fed her infant during the first 10.5 months of life while she was being treated with cyclosporine. Cyclosporine measurements in infant and maternal blood and breast milk revealed a mean breast milk/maternal blood level ratio of 84%, but undetectable levels in the infant. The infant grew and developed normally. CONCLUSION: The infant of a cyclosporine-treated mother was breast-fed exclusively during the first 10.5 months of life and did not absorb a detectable amount of the drug. Fetal growth and development were normal.
BACKGROUND:Cyclosporine is known to be excreted in breast milk, but levels in infants are not known. Post-transplant breast-feeding has been contraindicated in mothers treated with calcineurin inhibitors such as cyclosporine. CASE: A 35-year-old woman exclusively breast-fed her infant during the first 10.5 months of life while she was being treated with cyclosporine. Cyclosporine measurements in infant and maternal blood and breast milk revealed a mean breast milk/maternal blood level ratio of 84%, but undetectable levels in the infant. The infant grew and developed normally. CONCLUSION: The infant of a cyclosporine-treated mother was breast-fed exclusively during the first 10.5 months of life and did not absorb a detectable amount of the drug. Fetal growth and development were normal.
Authors: Cameron J McKinzie; Jillian P Casale; Jack C Guerci; Alyson Prom; Christina T Doligalski Journal: Paediatr Drugs Date: 2022-07-23 Impact factor: 3.930
Authors: Karolina Paziana; Magaly Del Monaco; Elyce Cardonick; Michael Moritz; Matthew Keller; Bruce Smith; Lisa Coscia; Vincent Armenti Journal: Drug Saf Date: 2013-05 Impact factor: 5.606